PDA Closure Guidelines

Indications for Closure

The American Heart Association recommends closure for adults with PDA and left atrial and/or left ventricular enlargement, or pulmonary arterial hypertension with net left-to-right shunting 1, 2, 3
The American Heart Association recommends closure for adults with PDA and prior history of endarteritis 1, 2, 3
The American Heart Association suggests closure is reasonable for asymptomatic small PDA by catheter device (Class IIa recommendation) 1, 3, 4
The American Heart Association suggests closure is reasonable for patients with pulmonary arterial hypertension and net left-to-right shunt 1, 3, 4
Closure is contraindicated in patients with pulmonary arterial hypertension and net right-to-left shunt (Eisenmenger physiology) 1, 3, 4, 5

Device closure via transcatheter approach is the method of choice for adults, as ductal calcification and tissue friability make surgical manipulation hazardous 1, 3, 6
Surgical closure is reserved for PDA too large for device closure 1, 2, 3
Surgical closure is reserved for distorted ductal anatomy precluding device closure (aneurysm or endarteritis) 1, 2, 3
Surgical closure is reserved for when concomitant cardiac surgery is required for other indications 1, 3

Ibuprofen is preferred over indomethacin due to reduced risk of necrotizing enterocolitis and transient renal insufficiency, with equal efficacy for PDA closure 5
Oral ibuprofen is as effective as IV ibuprofen and further reduces NEC risk compared to indomethacin 5
Dosing regimen: Initial dose 10 mg/kg IV, followed by 5 mg/kg at 24-hour intervals for two additional doses if needed 5
Monitor renal function before and during treatment, and assess for bleeding or bruising 5

Discharge from follow-up once complete closure is documented by transthoracic echocardiography 1, 3, 4, 5
Discontinue endocarditis prophylaxis 6 months after complete closure 1, 3, 4, 7
For device closure, follow-up every 5 years is recommended due to lack of long-term data 1, 3, 4
For small PDAs without left-heart volume overload, routine follow-up every 3-5 years is appropriate 1, 2, 3, 5

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for adult congenital heart disease state that anticoagulation or antiplatelet therapy is not indicated after either surgical ligation or transcatheter device closure of a patent ductus arteriosus in adults. 8, 9

Once complete closure is confirmed by transthoracic echocardiography, patients can be safely discharged from routine cardiology follow‑up. 8, 9
Endocarditis prophylaxis should be continued for up to 6 months after PDA closure and then discontinued once endothelialization is presumed complete. 8, 9
For patients who undergo device closure, a follow‑up echocardiographic assessment approximately every 5 years is advised because long‑term durability data are limited. 8, 9

Unlike prosthetic valve replacement, PDA closure does not place mechanical components in high‑flow cardiac chambers, eliminating the need for chronic anticoagulation. 10
Unlike peripheral artery disease (PAD) revascularization, PDA closure treats a congenital shunt rather than atherosclerotic disease, so antiplatelet or dual‑pathway inhibition is not indicated. 11

Patients with PAD who undergo revascularization require antiplatelet therapy (or dual pathway inhibition) to reduce atherothrombotic events, highlighting a key difference from PDA management. 11

Prescribing aspirin, clopidogrel, or systemic anticoagulation “just to be safe” after PDA closure confers unnecessary bleeding risk without demonstrated benefit. 8, 9
The only medication routinely considered after PDA closure is temporary endocarditis prophylaxis for the first 6 months until the occluder device is fully endothelialized. 8, 9